UNSPSC 51411805: Cetiedil citrate

This classification denotes a vasodilating agent with the molecular formula C20H31NO2S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IE65P4OE02, chemically known as 3-thiopheneacetic acid, alpha-cyclohexyl-, 2-(hexahydro-1h-azepin-1-yl)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) but more generally known as cetiedil citrate, which bears US NIH Compound Identifier 66383. Most nations, for tariff and trade purposes, schedule cetiedil citrate under HS 29349990 and SITC 51579.

As of Q4 2014, CETIEDIL CITRATE remains US FDA's Preferred Term for this commodity. Cetiedil citrate bears US NLM identifiers UMLS ID C0771456 and NCI Concept Code C79585. SMILES: C1CSCC1C(C2CCCCC2)C(=O)OCCN3CCCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51411805 Cetiedil citrate is a Commodity code that captures state and local procurement of advanced pharmaceuticals and prescription medications for emergency medical services, public health programs, and institutional healthcare delivery. Recent solicitations show state and local governments buying specific branded and generic pharmaceutical products—epinephrine, labetalol, adenosine, diltiazem, and other critical-care medications—through competitive sealed bids and cooperative purchasing frameworks, often with supply-chain requirements around expiration dating, cold-chain logistics, and FDA compliance. Issuing bodies include city fire rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances; the activity spans both emergency-response procurement (single-jurisdiction, item-specific bids) and large-scale multi-state contracts serving dozens of participating government entities. Tampa Fire Rescue and the Texas Health and Human Services Commission represent typical buyers in this space, with cooperative vehicles like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as significant aggregation platforms.

Recent opportunities cluster in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (four pharmaceutical line items totaling approximately $40,000) with a response deadline of April 8, 2026 and a one-year contract term plus renewal options; the solicitation included a 5 percent small-local-business-enterprise sheltered-market discount. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local jurisdictions with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and demanding cGMP and Drug Supply Chain Security Act compliance. The Texas HHS Commission issued RFI HHS0017013 in April 2026 seeking market intelligence on direct-to-manufacturer prescription fulfillment models, signaling future formal procurements in that state. All three recent opportunities emphasize pharmaceutical product compliance, expiration and shelf-life warranties, and established distribution-channel relationships, with cooperative purchasing frameworks displacing individual-jurisdiction spot buys as the preferred procurement method for larger-scale demand aggregation.